We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
IQVIA shares gained 41.5% in three months, outpacing its industry and the S&P 500 Composite.
R&DS net new bookings rose 19% to $3.2B, while contracted backlog reached $34.2B as of June 30, 2026.
IQVIA raised its 2026 revenue and EPS guidance, while 1H share repurchases totaled $950M.
IQVIA Holdings Inc. (IQV - Free Report) stock has rallied over the past three months. The company’s shares have jumped 41.5%, outperforming the industry’s 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick.
3-Month Share Price Performance
Image Source: Zacks Investment Research
Let us delve into the factors that have contributed to the company’s outperformance.
Record Net Bookings & Solid Backlogs
IQVIA’s net new bookings were $3.2 billion for research and development solutions (R&DS) in the second quarter of 2026. It marked 19% year-over-year growth, resulting in a book-to-bill ratio of 1.22X. As the metric surpasses 1, it implies that new order intake exceeds current revenue recognition.
RD&S’s contracted backlog was $34.2 billion as of June 30, 2026. In the second quarter of 2026, the company anticipated $9.2 billion in backlog to convert to top line in the next 12 months, suggesting a 7.5% year-over-year increase.
A high backlog with substantial probability of future revenue provides analysts and investors long-term visibility into top-line growth, lowering earnings uncertainty. Highly predictable and recurring revenues raise investor confidence.
Raised 2026 Outlook Lifts Investor Sentiment
In the second quarter of 2026, management uplifted revenue expectations to $17.28-$17.48 billion from the preceding quarter’s view of $17.15-$17.35 billion. The bottom-line prospect was raised to $12.8-$13 per share from $12.65-$12.95 provided during the first quarter of 2026.
A hike in top- and bottom-line guidance raises investors' confidence and prompts analysts to revise their financial models upward, resulting in higher price targets. Currently, based on short-term price targets provided by 19 analysts, the average price target for the stock is $265.26. It offers a 9.6% upside from the last closing price of $241.99.
Image Source: Zacks Investment Research
Shareholder-Friendly Actions
IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, IQV repurchased shares worth $1.24 billion. In the first half of 2026, the company’s share repurchases amounted to $950 million. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock.
View the Zacks #1 Rank List
Image: Bigstock
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
Key Takeaways
IQVIA Holdings Inc. (IQV - Free Report) stock has rallied over the past three months. The company’s shares have jumped 41.5%, outperforming the industry’s 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick.
3-Month Share Price Performance
Let us delve into the factors that have contributed to the company’s outperformance.
Record Net Bookings & Solid Backlogs
IQVIA’s net new bookings were $3.2 billion for research and development solutions (R&DS) in the second quarter of 2026. It marked 19% year-over-year growth, resulting in a book-to-bill ratio of 1.22X. As the metric surpasses 1, it implies that new order intake exceeds current revenue recognition.
RD&S’s contracted backlog was $34.2 billion as of June 30, 2026. In the second quarter of 2026, the company anticipated $9.2 billion in backlog to convert to top line in the next 12 months, suggesting a 7.5% year-over-year increase.
A high backlog with substantial probability of future revenue provides analysts and investors long-term visibility into top-line growth, lowering earnings uncertainty. Highly predictable and recurring revenues raise investor confidence.
Raised 2026 Outlook Lifts Investor Sentiment
In the second quarter of 2026, management uplifted revenue expectations to $17.28-$17.48 billion from the preceding quarter’s view of $17.15-$17.35 billion. The bottom-line prospect was raised to $12.8-$13 per share from $12.65-$12.95 provided during the first quarter of 2026.
A hike in top- and bottom-line guidance raises investors' confidence and prompts analysts to revise their financial models upward, resulting in higher price targets. Currently, based on short-term price targets provided by 19 analysts, the average price target for the stock is $265.26. It offers a 9.6% upside from the last closing price of $241.99.
Shareholder-Friendly Actions
IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, IQV repurchased shares worth $1.24 billion. In the first half of 2026, the company’s share repurchases amounted to $950 million. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock.
Zacks Rank & Stocks to Consider
IQVIA currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Medical sector are Anika Therapeutics (ANIK - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANIK has a long-term earnings growth expectation of 10%. Anika Therapeutics delivered a trailing four-quarter earnings surprise of 950%, on average.
BTSG has a long-term earnings growth expectation of 46%. BrightSpring delivered a trailing four-quarter earnings surprise of 16.1%, on average.